Israel’s Pharma Two B (see here previously) is presenting the full results of its Phase 3 trial of its once-a-day injection of its P2B001 treatment for Parkinson’s disease. P2B001 combines low-dose pramipexole with low-dose rasagiline. It relieves PD symptoms with few side effects.
https://nocamels.com/2023/08/revolutionary-jab-alleviates-parkinsons-symptoms-in-new-study/